Navigation Links
NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
Date:3/23/2011

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.  Previously, NephRx reported that NX002 had demonstrated significant efficacy when tested in well-validated animal models of oral mucositis.  Mucositis is a debilitating and often dose-limiting condition that affects more than 400,000 cancer patients who receive chemotherapy or radiation therapy in the U.S. each year.  Current treatment options are limited.

"Issuance of this most recent patent further confirms the promising utility of NX002 as a potential treatment for oral mucositis," said James Koziarz, President and CEO of NephRx.  "Mucositis is a painful and debilitating side effect of cancer therapy that can be dose-limiting, jeopardizing patients' chances for successful treatment.  We look forward to advancing the detailed NX002 toxicity studies needed to initiate the mucositis clinical program for NX002."

NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury.  Its multiple biological properties include the ability to protect cells from injury, stimulate cell growth and migration, and increase the accumulation of proteins that bind cells together.  In a study in a well-validated mucositis model, animals treated with NX002 had reduced levels of oral ulceration and a more rapid recovery, with no evidence of toxicity.  NephRx has begun the preclinical toxicology studies of NX002 needed to initiate mucositis clinical trials targeted for late 2011 or early 2012.

The U.S. Patent and Trademark office issued Patent No. 7910543, "Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors."  Rights to this patent,
'/>"/>

SOURCE NephRx Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
6. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
9. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... financial results for the second quarter ended June ... to see encouraging advancements in the US commercialization ... estimated total prescriptions and estimated total per week ... Arena,s President and Chief Executive Officer. "Other recent ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
(Date:8/1/2014)... 2014 Market Publishers Ltd announces ... been added to its catalogue. , ... (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, ... drivers include, among others, increasing ageing population, rising ... 2015, the pharma market in India is anticipated ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... Patients with the progressive, deadly respiratory ailment known as ... to battle the disease, the U.S. Food and Drug ... new treatment, an inhaled spray called Striverdi Respimat (olodaterol) ... which is often linked to smoking, involves multiple lung ... Patients with COPD may experience a number of symptoms, ...
(Date:8/1/2014)... parents worry about their children choking on small objects or ... Such was the case for 15-month-old Landon Jones who started ... "At the time, Landon had a cold so it ... illness or choking," recalled his mother, Ula Jones. But, ... his windpipe and had to be removed via surgery. Landon ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2
... activates p53 tumor-suppressor function without causing DNA damage , , ... targets a protein interaction involved in many types of ... , In cell cultures, the small-molecule inhibitor MI-219 was ... protein p53 from being blocked in the presence of ...
... of Telehealth capabilities to the ... they help across Canada., TORONTO, March 7 /PRNewswire/ - ... announce they have partnered with We,Care Health Services Inc. "We ... of services for those with chronic diseases,and their caregivers. We ...
... HOLLYWOOD, Fla., March 7, Cancer,s two ... "costs," and each holds capacity,to create patient ... the National Comprehensive Cancer Network,s 13th Annual,Conference, ... treatments, best practices dictate that,they follow guidelines ...
... Grey House Publishing and Penn,Hill Publications, based in ... Hudson,s Washington News Media Contacts Directory. In addition ... Media Contacts,Directory, Grey House is also proud to ... Directory., In 1968, Howard Penn Hudson completed ...
... Galderma Pharma, S.A.,announces an agreement with ZARS ... outside the USA and Canada for promotion and,distribution ... follows,an agreement signed last year between Galderma and ... in the USA and Canada., "This agreement ...
... The rheumatoid arthritis (RA),treatment market, held back somewhat in ... and Bextra, is rebounding due to the,performance of biologic ... $12 billion in 2006 and -- driven by new ... year through 2011,according to a new report by Kalorama ...
Cached Medicine News:Health News:Researchers Design Promising Cancer Drug 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 3Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 2Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 3Health News:Grey House Publishing Acquires Hudson's Washington News Media Contacts Directory 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 3Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2
... This remarkable anti-reflux valve ... plastic housing which prevents the ... closed when in sitting or ... virtually self-cleaning and interference free ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
Medicine Products: